CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6 enrolled
Drug / intervention
Lamotrigine +1 moredrug
Likely dose
Lamotrigine 25–50 mg tabletsAI-extracted
Key inclusion· 6
  • ✓Age 18–60 years
  • ✓Right-handed, non-smoker
  • ✓Diagnosed with facial pain
  • ✓Continuous facial pain for >3 months
Key exclusion· 8
  • ✕Current depression
  • ✕History of allergy to anticonvulsants
  • ✕Significant medical problems
  • ✕Abnormal EKG

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00243152
NCT00243152N/ACompleted
CompareCT.gov

Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

Pain and Analgesia Imaging and Neuroscience Group·interventional·Posted Oct 21, 2005·Updated Dec 7, 2018

In Brief

A clinical study evaluating Lamotrigine and Placebo (for Lamotrigine) for Facial Neuropathy. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine (trade name Lamictal) on neuropathic facial pain or neuralgia using functional magnetic resonance imaging (fMRI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFacial Neuropathy
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 21, 2005
Enrollment StartOct 1, 2005
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.7 years ago

Interventions

Lamotriginedrug

: 25mg and 50mg tablets

Placebo (for Lamotrigine)drug

Sugar pill manufactured to mimic Lamotrigine tablets